Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

NCT01870726 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Interventions

DRUG: INC280
DRUG: Buparlisib

Sponsor

Novartis Pharmaceuticals